InvestSMART

BlinkLab Limited (ASX:BB1)

ALERT: Price-sensitive ASX Announcement for BB1
Current share price for BB1 : $0.565 -0.21 (-27.10%)+
Announcement
Release
24 Mar 2026 9:35AM
Price at Release
$0.775
Full Release
download
Summary
BlinkLab Limited, listed on the ASX under the symbol BB1, has announced the commencement of its pivotal validation program for the FDA 510(k) submission with the first participant successfully enrolled and tested using BlinkLab Dx1. This marks a significant milestone as the company progresses towards its FDA submission targeted for the end of 2026. The study, led by IQVIA-MCRA, follows a successful pilot phase where BlinkLab Dx1 showed strong diagnostic performance, exceeding sensitivity and specificity targets. The validation program is designed to provide essential clinical and usability evidence required for FDA submission, with participant recruitment expected to conclude in about eight months.
Key Points
  • BlinkLab Limited has commenced the pivotal validation program for FDA 510(k) submission with the enrollment of the first participant.
  • The study is conducted by BlinkLab’s CRO partner, IQVIA-MCRA, to ensure adherence to protocols and regulatory requirements.
  • BlinkLab Dx1 demonstrated 83.7% sensitivity and 84.7% specificity in a pilot study, surpassing target performance thresholds.
  • The 510(k) FDA submission is expected by the end of 2026, with participant recruitment anticipated to complete in approximately 8 months.
  • The study includes a usability phase transitioning into clinical validation without further announcements, assessing diagnostic performance against standard-of-care assessments.
  • The main study phase involves a network of 10 leading U.S. clinical sites.
  • BlinkLab’s device is intended as a diagnostic aid to support clinical decision-making through digital biomarkers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.